| dc.description.abstract | The development of nanomaterials to enhance the efficacy of anti-cancer drugs is being
increasingly focused on and developed worldwide. Nano-carriers were deemed to play a
crucial role in the improvement of pharmacokinetics and pharmacodynamics of various
anti-cancer drugs, thereby increasing their effectiveness in cancer treatment. In this study,
a drug-loaded nanogel system based on Alg combined with Brij S100 was formulated.
The structure of the Alg- Brij S100 was evaluated using 1H-NMR spectroscopy and FT IR infrared spectroscopy. After combining Alg and Brij S100, a micelle structure was
formed at a concentration of 574.6 ± 16.3 µg/mL. The efficiency encapsulation of RE in
the nanosystem was tested using UV-Vis spectrophotometry was 91.3%, and the ratio of
RE content to the Alg-Brij S100 nanogel system was 4.3%. The particle size of Alg- Brij
S100 was determined by dynamic light scattering (DLS) and was found to be 19 ± 0.36
nm. This small size could be advantageous for transport and uptake, as it facilitates
penetration into tissues and cells. The release of RE from the nanogel system at pH 7.4
and 5.5 was 47.5% and 49.7%, respectively within 48 hours and following a Fickian
diffusion. Moreover, cytotoxicity assays for carriers conducted on mouse fibroblast cells
(L929) showed cell viability of 168.81 ± 10.57%, 145.27 ± 6.93%, and 156.72 ± 12.56%
at concentrations of 500 μg/mL, 250 μg/mL, and 125 μg/mL respectively which indicates
good biocompatibility and proliferation of the nanogel system. Additionally, Alg- Brij
S100/RE (IC50 = 26.25 ± 1.88 µg/mL) was found to exhibit better cytotoxicity against
MCF7- breast cancer cells compared to free RE (IC50 = 34.75 ± 1.57 µg/mL). These
findings suggest that the Alg- Brij S100 nanogel system loaded with RE holds potential
as a drug delivery system for breast cancer. | en_US |
